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Abstract: Recent discoveries in zinc biology provide a new platform for discussing the primary
physiological functions of mammalian metallothioneins (MTs) and their exquisite zinc-dependent
regulation. It is now understood that the control of cellular zinc homeostasis includes buffering of
Zn2+ ions at picomolar concentrations, extensive subcellular re-distribution of Zn2+, the loading of
exocytotic vesicles with zinc species, and the control of Zn2+ ion signalling. In parallel, characteristic
features of human MTs became known: their graded affinities for Zn2+ and the redox activity
of their thiolate coordination environments. Unlike the single species that structural models of
mammalian MTs describe with a set of seven divalent or eight to twelve monovalent metal ions,
MTs are metamorphic. In vivo, they exist as many species differing in redox state and load with
different metal ions. The functions of mammalian MTs should no longer be considered elusive or
enigmatic because it is now evident that the reactivity and coordination dynamics of MTs with Zn2+
and Cu+ match the biological requirements for controlling—binding and delivering—these cellular
metal ions, thus completing a 60-year search for their functions. MT represents a unique biological
principle for buffering the most competitive essential metal ions Zn2+ and Cu+. How this knowledge
translates to the function of other families of MTs awaits further insights into the specifics of how
their properties relate to zinc and copper metabolism in other organisms.
Keywords: metallothionein; thionein; zinc; copper; metamorphic proteins; affinity
1. A 60-Year Old Conundrum about a Protein’s Function
The story of metallothionein began with the discovery of a cadmium-containing protein in horse
kidneys in the 1950s [1]. The name metallothionein (MT) originated from the protein’s variable
metal content and its relatively high amount of sulphur [2]. Cadmium accumulates in MT with
exposure and age. However, the metal ions most relevant biologically are zinc (Zn2+) and copper
(Cu+). A charge difference—later shown to be due to the presence or absence of the amino acid Asp
at position 10—allowed separation of two major forms by ion exchange chromatography and led to
the designation of them as MT1 and MT2. MT1 in most mammalian species has many related genes
(paralogues) and the resulting proteins can be resolved on reversed phase HPLC columns [3]. In an
unrooted evolutionary tree, MT2 groups closely with MT1 proteins, which have at least 8 functional
genes in humans [4]. Two additional forms, MT3 [5], a neuronal growth inhibitory factor, and MT4 [6],
present in squamous epithelia, were found much later and are evolutionarily more distantly related.
Horse kidney MT1B was sequenced twenty years after the discovery of the protein [7]. The sequence
showed characteristic spacings of cysteines and the absence of aromatic amino acids. It took yet another
10+ years to obtain 3D structures of hepatic MTs with both X-ray crystallography (rat MT2), showing
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the entire molecule, and NMR spectroscopy (human MT2), showing the individual domains but not
how they interact [8,9]. The peptide chain folds into two separate domains, each organizing two
Zn2+–sulphur(thiolate) clusters, one with 3 Zn2+ and 9 Cys (β-cluster) and the other with 4 Zn2+ and
11 Cys (α-cluster). In both clusters, all metal ions are in tetrathiolate coordination environments, which
is possible only through the use of cysteine sulphur as a donor bridging two metal ions. It is important
to realize that these structures are based on either a species induced in vivo with Cd2+ [9], which
remarkably has two Cd2+ ions in the N-terminal β-domain at defined positions, or a species where all
the metal ions had been removed, all the cysteines reduced, and the protein was reconstituted with
seven Zn2+ or Cd2+ ions. In vitro, MTs can bind more than seven equivalents of metal ions [10,11]. Thus,
for structural studies the proteins were brought into chemically defined “homogeneous” forms—a
requirement for most biophysical methods to obtain molecular structure—whereas the inherent
heterogeneity of the protein in vivo provides a clue to its functions. It is therefore critical to understand
that the forms for which structures exist do not present the dynamic state of the protein in vivo.
Metalloproteins with multiple and similarly spaced cysteine residues were found in many
non-mammalian species and are also called metallothioneins or metallothionein-like [12]. Sequence
similarity and information on genomic DNA such as introns, exons, and the presence of cis acting
elements formed the basis for a classification of metallothioneins into 15 families [13]. 8156 entries (1657
nucleotide sequences and 6499 expressed sequence tags (ESTs) for MTs from various species were in the
National Center for Biotechnology Information (NCBI) nucleotide database in April 2017. In addition,
classification of plant MTs, which have significant variability in primary structures, required the
definition of four families [14]. It is important to acknowledge that the common evolutionary
origin of MTs has not been established, however. Taxonomic distribution has been reported but
not phylogenetic relationship based on a rooted tree. This lack of information is problematic if the
term metallothionein is used to imply a functional relationship across phyla—a fallacy in many
scientific reports. Furthermore, the 3Zn2+–9Cys (Zn3S9) cluster of the β-domain of MT is found in the
SET domain of histone lysine methyltransferases [15] and the CXC domain of male-specific lethal 2
protein [16], clearly demonstrating a functional context of the metal-binding motifs outside the MT
family. Many criteria have been discussed to define what constitutes a metallothionein, but for any
of them exceptions were found. The definition, therefore, falls back to what the name initially was
meant to express: proteins that have metal ions and thiol(ate) sulphur. It must be understood that the
name does not describe a function but a generic property like, for example, the cysteine knot proteins.
To avoid generalizations about MTs in other phyla, we will focus here only on human MTs, with
occasional reference to other mammalian MTs as appropriate, necessary, and indicated. We believe
that a deductive approach to determine biological function is flawed in the case of the accumulated
sequences of so-called MTs and that an inductive approach is necessary instead.
“Metallothionein” is a vast and multifarious subject. With only properties of the protein known,
how can one find out its natural function(s)? The search for a function has been on-going for over
60 years and reached a nadir when the phenotypes of Mt1/Mt2 k.o. mice indicated that these
proteins are not essential under laboratory conditions and accordingly the function was thought
to be elusive [17–19]. However, in these experiments the phenotype with regard to zinc metabolism
was never tested, and when it was tested later, a lot of important observations were made, all of which
in fact do point to specific functions [20]. Many genetic polymorphisms of human MTs have been
described. Some of them result in mutations in the proteins that are associated with multiple effects on
human health and also point to specific biological roles of MTs [21].
The generally quoted functions of MTs are believed to be in the metabolism of toxic metal ions,
i.e., Cd2+, the metabolism of essential metal ions, i.e., Zn2+ and Cu+, and as antioxidants or radical
scavengers. One function focuses on metal ion binding and the other focuses on thiol reactivity, while
in fact the two are linked with important consequences. Two developments, we believe, require
re-evaluating the basic tenets of structural studies as they provide clues to the functions of MTs.
One development is information about metal ions binding to MTs in vivo and the other is about the
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affinity of metal ions for the protein, the most important property for its function in metal metabolism.
At issue is the assumption that the form with 20 reduced cysteines and seven Zn2+ ions made in vitro
and used for deriving structural models is the only form of the protein. As indeed noticed early on,
in vivo MTs have variable metal ion content under different conditions (Table 1), and even for a single
metal ion such as Zn2+ the occupancy is variable. Also, an antioxidant function implies different redox
states of the protein, for which there is evidence as well. For example, under conditions of oxidative
stress MT containing a disulphide bridge has been isolated [22]. By using rapid chemical modification
assays, we have shown that the protein in cultured human cell lines is neither saturated with Zn2+ nor
fully reduced [23,24].
Table 1. Metal composition of native mammalian metallothioneins (MTs).
Formula Source Reference
Zn, Cd, Cu horse kidney [1]
Cd0.2Cu0.1Zn6.7MT human liver [25]
CuZn6MT human corneal epithelial cells [26]
Zn7MT same cells, induction with Zn2+ [26]
Cu4Zn3MT3 human brain [5]
Cu2Zn5MT4 mouse tongue * [6]
Cd2Zn5MT2 rat liver, induction with Cd2+ [9]
Cd3Cu3ZnMT2 mouse liver, induction with Cd2+ [27]
Cd4CuZn2MT1 mouse liver, induction with Cd2+ [27]
Cd6CuMT1/MT2 mouse liver, induction with Cd2+ [27]
* Based on a measured metal ratio of 2.6 and an assumed stoichiometry of seven bound divalent metal ions.
The two properties are linked: Metal occupancy determines thiol reactivity and thiol reactivity
determines metal ion binding characteristics. The resolution of the underlying conundrum of
apparently different functions is that the Zn2+-thiolate clusters are redox-active in the cellular
environment. It allows coupling the redox-inert Zn2+ ion to redox metabolism by using redox-sensitive
MT to provide more Zn2+ under oxidative conditions and less Zn2+ under reductive conditions,
thus establishing a role for redox changes in zinc availability and distribution [28,29]. The term
“metallothionein” (MT) refers to several possible forms of the same protein, which differ with regard
to the bound elements, metal load and redox state. To avoid confusion due to this generic nature
of the term, we will use “metallothionein” or “MT” to refer to a particular protein isoform with a
unique amino acid sequence without considering its native heterogeneity. Whenever possible, we
will additionally specify the particular states in terms of metal load and oxidation state, using a
nomenclature that identifies the molecular species relevant to function.
While the affinity of MT for Zn2+ is high overall, originally reported binding constants were
estimates only and the methods used at the time did not have the resolution to determine small
differences in affinities of particular metal ions in such a complex system. When we investigated the
affinities with higher resolution methods, we found a distribution of affinities and binding of one Zn2+
ion with lower affinity in human MT2A [30]. This is chemically perhaps not remarkable: Though the
Zn2+ ions are all in tetrathiolate coordination environments, there are differences in the number of
bridging and end-on ligands, and in neighbouring amino acid residues of the metal-binding cysteine
sulphurs. The best demonstration that the seven coordination environments are different is provided by
113Cd or 111Cd-NMR spectroscopy which can resolve all seven metal ions into individual peaks [31,32].
But it is remarkably for biology that the difference in affinities rules out that MT is a thermodynamic
sink for cellular Zn2+, i.e., a protein in which Zn2+ ends up due to binding with the highest affinity
among all zinc proteins. Our findings support the opposite function, namely the active participation of
MT in Zn2+ re-distribution. Quantitative investigations of zinc affinities of other proteins now confirm
that MT does not have the strongest Zn2+ binding sites [33]. Other proteins, frequently with mixed
S2N2, S3N coordination environments, such as the PDLIM1 protein and transcription factors with a
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classical ββα fold (logKb ≈ 14) and the intermolecular zinc hook site of the Rad50 protein (femtomolar
affinity) bind Zn2+ ions much more tightly than MT, putting MT in the middle of the action rather than
at its periphery [33–36].
Significantly, all postulates and speculations about the functions of the protein in metal metabolism
made in the last sixty years have been in vain because the molecular aspects of the control of cellular
zinc homeostasis were not known. Only now with new knowledge gradually emerging in the last 10+
years on how cellular Zn2+ is regulated, a role of MTs in zinc metabolism can be formulated. It is now
established that Zn2+ is bound with rather high affinity to cellular zinc proteins and that the availability
of free Zn2+ ions accordingly is very low. In chemical terms, this means that Zn2+ is buffered at high
pZn (−log([Zn2+]free) and Cu+ even at higher pCu (−log([Cu+]free). There is no storage for Zn2+ in a
protein akin to ferritin for Fe3+. Instead there are controlled (gated) vesicular stores for Zn2+ in the
cell. For efficient buffering, there needs to be a surplus of coordination sites that are not occupied with
metal ions [23]. In this regard, the properties of MT are significant. Its affinity for Zn2+ matches cellular
pZn values and it has unoccupied metal-binding sites available for buffering. The term “unoccupied”
has a special meaning in the case of MT. It does not necessarily refer to donors of ligands not bound to
a metal ion such as in a metal-depleted active site of a metalloenzyme. Instead, it refers, at least in part,
to the additional metal binding capacity during the transition of isolated tetrathiolate coordination
environments with only end-on ligands—a maximum of five Zn2+ ions bound to twenty cysteines—to
the clusters with bridging ligands—seven Zn2+ ions bound to twenty cysteines. In addition, for copper
buffering, it refers to one metal ion (Cu+) displacing a less competitive metal ion (Zn2+) in an already
occupied site. These inherent properties of MTs are indeed remarkable features of a uniquely biological
metal-buffering molecule. An even and specific stoichiometric metal/ligand ratio is a chemical concept
with limited applicability to biology, because in vivo the availability of metal ions is controlled and
dictates stoichiometric or even non-stoichiometric ratios. Also, it is now established that Zn2+ ions have
signalling functions akin to Ca2+ ions [37]. This is the second reason why a molecule such as MT with
fast Zn2+ binding and dynamic regulation is needed for buffering signalling zinc ion transients. Thus,
while we are beginning to realize the intricacies of cellular zinc regulation, an understanding develops
on how the properties of MTs relate to functions in zinc metabolism. In retrospect, one realizes that a
function of MT in zinc or copper metabolism could not have been foreseen earlier because it was not
known how these metal ions are regulated and the molecules regulating them were not even known.
Only now the affinities of MTs for Zn2+ can be understood in terms of how Zn2+ is regulated, i.e.,
buffering both steady state and transient levels of Zn2+. MT clearly fulfils a very important function.
Research on the detailed MT functions in zinc and copper metabolism is just beginning and will
intensify in the future with a concomitant understanding of zinc fluxes and transients in real time and
cellular space, and how differences in affinity, redox potential, and differences among MT isoforms
control Zn2+ in different tissues.
Many scientific articles state that the function of MT is elusive or enigmatic. Yet the potential
functions and the functional potential of mammalian MT in zinc metabolism have been discussed
repeatedly [38,39]. The full implications of a role in zinc metabolism could not have been known at
that time because the two dozens of zinc transporters that participate in the control of cellular zinc
homeostasis and the concept of signalling Zn2+ ions were not known. While the protein’s functions
point to Zn2+ (and Cu+) metabolism, the regulation of the MT genes also point to Zn2+ metabolism,
and this latter fact also has not been discussed in sufficient detail. The regulation of gene expression of
MTs by many factors is a most dynamic system, exactly what is needed for dealing with such a critical
cellular ion as Zn2+, and it adds significant additional support for a role of the mammalian MTs in
zinc metabolism. Clearly, making this connection for non-mammalian MTs will require additional
information on their properties in relation to the specifics of zinc and copper metabolism in the
particular organisms.
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2. Relationships among Human Metallothioneins
An unrooted phylogenetic tree of human MTs shows a clear separation of MT3 and MT4 from
the other MTs that branch out [40]. In the branch, MT2 is close to MT1G and F, i.e., MT2 and MT1 are
much more closely related to each other than to MT3 or MT4. MT2 is a member of the MT1 branch.
The multiplicity of MT1 forms in humans has been observed in many other mammalian species but
apparently not in mice [41]. The reason for this gene multiplication is not clear. It is also not entirely
clear how many functional human MT1 proteins exist. Fourteen tightly linked MT genes (MT2A
and thirteen MT1 genes, including six genes not previously described) were localized on human
chromosome 16q13 [42]. In the order the MT1 genes occur on the chromosome, they are named 1L,
1E, 1K, 1J, 1A, 1D, 1C, 1B, 1F, 1G, 1H, 1I and 1X. Upon further examination of the six novel genes
(1I, 1J, 1K, 1L, 1H, 1X), it was concluded that only 1H and 1X are functional genes while the others,
including 1D, are pseudogenes [42,43]. Some authors [40] agree with us [4] on MT1A, MT1B, MT1E,
MT1F, MT1G, MT1H, and MT1X being functional proteins, but list MT1K (also known as MT1M) as
expressed and MT1L (also known as MT1R) as a pseudogene [4]. Minimally, there are eight MT1s plus
MT2, MT3 and MT4, i.e., 11 functional proteins. The branch that contains closely related MT2, MT1G,
and MT1F is more distantly related to MT1H, MT1X. Another branch contains MT1A, MT1E, MT1B,
MT1K (MT1M), and MT1J (pseudogene). There is an urgent need to curate databases and agree on the
nomenclature. Without agreement on a function of MTs, of course, it is difficult to make a judgement
as to whether or not a particular form is functional. An assignment as a pseudogene, in part, rests
upon the occurrence of amino acids that are atypical for MTs. Table 2 presents UniProtKB/Swiss-Prot
entries, as well as annotation scores of MT isoforms along with their natural variants. This list differs
from the one given above [40] where MT1L (MT1R) is listed as a pseudogene.
Table 2. Human metallothionien isoforms UniProtKB/Swiss-Prot, annotation score (from 0 to 5),
information on protein or transcript level, and natural protein variants. Entry number of MT4
is provided from the NCBI data base due to the wrong protein sequence deposited in UniProt
(MT4_HUMAN, P47944), which refers to an MT4 variant (30C→ Y, R31→W).
MT Isoform Number ofAmino Acids UniProt Name Entry Number
Annotation
Score
Protein
Existence * Variants
MT1A 61 MT1A_HUMAN P04731 5 PL T27→N, K51→ R
MT1B 61 MT1B_HUMAN P07438 4 PIH -
MT1E 61 MT1E_HUMAN P04732 5 PL -
MT1F 61 MT1F_HUMAN P04733 5 PL -
MT1G 62 MT1G_HUMAN P13640 5 PL A10 deletion(isoform 2)
MT1H 61 MT1H_HUMAN P80294 5 PL -
MT1L (MT1R) 61 MT1L_HUMAN Q93083 3 TL -
MT1K (MT1M) 61 MT1M_HUMAN Q8N339 4 PIH T20→ K
MT1X 61 MT1X_HUMAN P80297 5 PL -
MT2 61 MT2_HUMAN P02795 5 PL A42→ V
MT3 68 MT3_HUMAN P25713 5 PL -
MT4 62 Metallothionein4 AAI13443.1 3 PIH
30C→ Y, R31→
W, G48→ D
* PL: experimental evidence at protein level; PIH: protein inferred from homology; TL: experimental evidence at
transcript level.
3. Galvanization of Human Metallothioneins’ Gene Expression
In contrast to single functional genes for MT2, 3 and 4, multiple functional genes for MT1 are
present in the human genome [42,43]. A plethora of factors and conditions control basal and induced
expression of MTs. In addition, gene expression is controlled by promoter methylation and histone
modifications, where zinc-dependent proteins and events play a role. The human MT2 (MT2A)
promoter has cis-elements for binding of the transcription factor Sp1 (a zinc finger protein), eight
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sites for binding of MTF-1 (metal-response element (MRE) binding transcription factor-1, a zinc finger
protein), one site for AP1 binding, overlapping with one for AP4, three sites for AP2 (binding sites for
activator proteins—transcription factors responsive to different signalling pathways), a glucocorticoid
responsive element binding proteins from the nuclear hormone receptor family, which have zinc twist
motifs, and an interferon-sensitive response element for interferon alpha signalling [44]. The human
MT3 promoter includes sites for binding of Sp1, AP-2, MTF-1, and an astrocyte-specific transcription
factor [45]. Human MT4 expression is developmentally regulated. The following summary is based on
experimental evidence and in silico analyses of the promoters of human MT1 genes [40]. Zinc features
prominently in basal transcriptions factors (Sp1, MTF-1), in many of the transcription factors involved
in the induction (Table 3), and in repressors of MT gene expression. Zinc binding includes different
types of zinc motifs: zinc fingers (1Zn2+), zinc twists (2Zn2+) and zinc clusters (2–3Zn2+). Multiple
cis-elements are present in the genes of the MT1 family (Table 3). With few exceptions, at least seven
Zn2+-dependent proteins are involved in the induction of a particular MT. MTF-1 is a basal transcript
factor and also involved in the induction of MT depending on which and how many MRE cis-elements
on the promoter it uses, and its repression. If one adds up the Zn2+ ions needed for e.g., induction of
MT1A, assuming that all cis-elements are used, one calculates that 30 Zn2+ ions are present in all the
transcription factors. In such an analysis of gene expression, only the downstream Zn2+-dependent
transcription factors are examined. Of course, additional Zn2+-dependent events occur upstream in the
signal transduction pathways to these transcription factors. MT itself is involved in activating MTF-1.
For example, cadmium-induced MT expression proceeds through Cd2+ displacing Zn2+ in MT and
the released Zn2+ then activating MTF-1 [46,47]. MT also modulates glucocorticoid responsiveness of
cells [48]. Thus MT participates in controlling the occupancy of Zn2+-dependent transcription factor
with Zn2+ either through its role in buffering Zn2+ or in delivering Zn2+ to the transcription factors
directly. A specific sensor for copper has not been identified in eukaryotes. Like Cd2+, Cu+ displaces
Zn2+ from MT and the released Zn2+ then induces thionein through MTF-1 in order to buffer any
surplus of Cu+ (Figure 1).
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Four negative regulators have been identified for MT2A: MTF-1, NF-I/CTF, which binds to a
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There are significant differences in the promoters of the genes of the MT1/MT2 branch (Table 3).
Table 3. Zinc-dependent transcription factors for human MT1 genes. The numbers designate cis acting
elements in the promoters of the different MT1 genes [40].
Transcription Factor * Sp1 MTF1 EGR1 GR RAR Ikaros Churchill
Zinc Motif ZnFinger 6ZnFingers ZnFinger ZnTwist ZnTwist ZnFinger ZnFinger/ZnCluster
MT1
A 5 2 4 1 2 2 1
E 1 1 3 6 1 2 6
J (pseudogene) 2 2 3 1 3 4 8
B 1 4 - 1 5 8 3
K/M 4 2 8 2 2 2 9
G 5 2 - - 3 6 6
F 8 5 5 - 5 6 8
H 2 5 - 3 3 7 5
X 3 3 4 2 3 9 5
* Sp1: specificity protein 1; MTF1: metal-response element (MRE) binding transcription factor 1; EGR1: early growth
response protein 1 (also known as Zif268 (zinc finger protein 225) or NGFI-A); GR: glucocorticoid receptor; RAR:
retinoic acid receptor; Ikaros: IKZF1; Churchill: chch.
In part, these differences relate to tissue specific expression of MTs. The underlying differences
have not yet been linked with any tissue specificity of zinc metabolism. Nor has the vast information
about differential gene expression of MTs in cancer and other pathological conditions been explained
in terms of specific effects on zinc or copper metabolism. Analysis of mRNA levels or protein levels—if
suitable antibodies are available—provides no information on either the redox state or the metal load
of the protein. Because MT gene expression is very sensitive to pathological changes in addition to
many forms of stress, and environmental and developmental changes it could serve as a surrogate
for yet to be defined changes in metal and redox metabolism under these conditions. Suffice it to
say that observed changes in gene expression of MTs in cancer cells are entirely consistent with
de-differentiation and proliferation of cells and the critical roles Zn2+ has in these processes.
4. Function in Human Cellular Zinc Metabolism
Gene expression studies cannot answer the question how the function of the expressed MTs relate
to redox and metal metabolism and to donating or accepting Zn2+/Cu+. As for many proteins there is
very poor correlation between MT mRNA level and MT protein level [49]. Here, too, using a consistent
nomenclature would improve our understanding. While most authors use the term metallothionein
for the expressed protein, the protein made on the ribosome is thionein (T), not metallothionein.
Whether newly synthesized T becomes MT depends on the availability of metal ions, which in the
case of the highly competitive Zn2+ and Cu+ ions is very limited and highly controlled. MT is a metal
donor while T is a metal acceptor. Functionality of the two protein forms therefore is opposite and
can be determined only with regard to information about metal occupancy on the protein level. But
establishing functionality of the individual MTs is almost never pursued with assays that determine
metal load and redox state. We have developed such assays for determining the overall metal load
of all MTs present in a cell or tissue, i.e., the MT/T ratio [50]. The value of this ratio determines zinc
availability. At high ratios, more Zn2+ is available; at low ratios, less Zn2+ is available as expected for
a metal buffer. In rat organs, the percentage of apoprotein (T/(T + MT)) varies from 9% in testes to
53–54% in brain and kidneys [50]. In vitro investigations demonstrated that varying the MT/T ratio
indeed controls the potential of MT to serve as a donor of Zn2+ for apoproteins [51]. Changes in MT
expression affecting the overall amount of the protein are also important. They adjust the buffering
capacity of the cell. Buffering capacity is the second property of a buffer and different from adjusting
a particular pZn. It determines how resistant the system is to a change in pZn when the total Zn2+
concentration changes. Altering metal buffering is critical for the physiology of a cell. Different states
of the same cell, i.e., proliferating, differentiating, and apoptotic cells have different zinc buffering and
accordingly different pZn values [23].
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High Zn2+ ion concentrations induce T to bind and buffer Zn2+ (and Cu+). How the cell senses
when its Zn2+ concentration is too low is a different matter and not resolved. The induction of T at
high Zn2+ ion concentrations seems to relate mostly to conditions of binding an excess of metal ions,
which is a function of T in accepting metal. An important issue was to demonstrate that T exists under
steady state conditions and in which form, i.e., whether it is entirely in the apoform or a protein that
contains less than seven metal ions. Whether T can co-exist with fully-loaded MT depends on whether
there is a high degree of positive cooperativity in metal binding promoting the co-existence of the two
species. The issue of cooperativity will be addressed later. In many cancer cell lines, evidence for T
was provided [52]. We addressed the question of whether T exists in tissues by employing a rapid
chemical modification of thiols. The results provided further evidence that the protein is not fully
saturated with metal ions, exactly what one expects from a metal buffer [50]. However, an important
distinction must be made when using the term thionein (T). The completely metal-free form of the
protein can be made in vitro but based on the metal binding properties and the availability of metal
ions in biological systems T does not exist in vivo, with the possible exception of its fleeting existence
when it is made on the ribosome.
It is now established that the cellular Zn2+ concentration is tightly regulated by zinc transporters,
exporters and importers and that transient increases in cellular Zn2+ concentrations are employed
for cellular signalling. The individual molecules controlling cellular zinc homeostasis, including MT,
are interconnected and do not work in isolation. This information was not available twenty years
ago when the function of MT was deemed elusive. Regarding mobilization of Zn2+ for signalling
purposes there are at least three different pathways [53]: (i) release of Zn2+ from cells by vesicular
exocytosis, which has to be followed by “soaking up” the Zn2+, e.g., in the synaptic cleft; (ii) the release
of Zn2+ at the endoplasmic reticulum by hormone-triggered phosphorylation of the zinc transporter
ZIP7 [54]; and (iii) Zn2+ release through signalling with reactive species such as hydrogen peroxide,
nitric monoxide or yet others from redox-sensitive thiolate coordination environments. These events
generate different spatiotemporal distributions of signalling zinc ions. As with calcium ions, the
steady state needs to be re-established after the signalling event occurred. MT indeed influences these
zinc signalling events in the cell [55] and therefore its expression is a major factor in modulating and
controlling zinc-dependent cellular signalling.
5. Metal Composition: Native Mammalian Metallothioneins Contain Copper
Table 1 summarizes the metal composition of native MTs. It shows the variable metal content
of MTs and, importantly, that copper is bound in all instances where MT was not induced by zinc,
albeit there remains some uncertainty as to the extent to which it is present owing to the procedures
employed in isolating the protein. Remarkably, in cadmium-exposed rats, plasma MT also contains
copper [56]. Moreover, the metal composition of MTs depends on age, e.g., with a linear increase of
Cd2+ with age, and on diseases associated with zinc and copper metabolism [57,58]. The presence of
Cu+ ions in native MTs, in particular MT3 and MT4 (Table 1), does not seem to be an artefact of the
isolation of MT from tissues and suggests a role in copper metabolism. Human foetal and neonatal MTs
contain significant amounts of Cu+ as also reported for MTs from other species [59,60]. Zinc and copper
MTs are differentially distributed: CuMT can be found in lysosomes under conditions of excess copper
while Zn-MT is mainly cytosolic [61]. Since the Cu–S(thiolate) bond is more thermodynamically stable
as well as kinetically labile than the Zn–S(thiolate) bond, CuMT can exist under the acidic conditions
in lysosomes [61]. Whether Cu+-only MTs co-exist with Zn2+-only MT is not known. In diseases
associated with copper accumulation, e.g., Wilson disease, hepatic cellular carcinoma, primary biliary
cirrhosis and certain animals such as the Long-Evans cinnamon rat, Bedlington terrier, and toxic milk
mouse, more Cu+ is sequestered in MT [62]. Many tumours have a higher copper content, in particular
melanoma [63].
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In a murine model of Menkes disease, copper accumulates in intestinal cells and a large fraction
is bound to MT. Crosses of the disease model and Mt1/Mt2 k.o. mice revealed a high degree of copper
toxicity and demonstrated a physiological function of MT in Cu+ sequestration [64].
6. Cu+ Affinity for Metallothionein
In the first period of 3d metals, Cu2+ has the strongest affinity to ligands [65]. Accordingly, its free
metal ion concentration is the lowest among the divalent essential biometals. In biological systems,
the situation is more complex due the fact that Cu+ is the preferred redox state under the reducing
conditions in cells. Yet, the valence state of copper in some cellular proteins is Cu2+. For yeast copper
superoxide dismutase, it has been estimated that the binding constant for Cu+, Kb about 1020 M−1,
is about five orders of magnitude higher than the one for Cu2+, Kb about 1015 M−1 [66]. Likewise,
murine S-adenosylhomocysteine hydrolase has a Kb of 3.8 × 1014 M−1 for Cu2+ [67]. Thus, the cellular
concentration of free Cu2+ is potentially higher than the one for Cu+ based on these equilibrium
considerations but any free Cu2+ is expected to be reduced to Cu+. The high toxicity of Cu+ would
seem to require an efficient buffer that avoids its exquisite Fenton chemistry which results in formation
of reactive oxygen species. Estimates of binding constants of Cu+ to MT are Kb > 2 × 1016 M−1 [68];
4.1 × 1016 M−1 [69]; and 2.1 × 1015 M−1 in case of Cu12MT3 [70]. This high affinity suggests that MT
buffers Cu+ to at least femtomolar concentrations. If one considers that the volume of a typical cell is in
the range of a few picoliters (10−12 L), such a concentration is at the single ion per cell concentrations,
essentially solving the issue of how to avoid Fenton chemistry. Moreover, to avoid Fenton chemistry
during transfer of copper, cellular Cu+ traffic is mediated by metallochaperones. In the absence of bona
fide zinc metallochaperones, MT can have an active role in cellular Zn2+ re-distribution. Furthermore,
the presence of both Zn2+ and Cu+ in MT indicates an effect of copper on zinc buffering and vice versa.
The role of human MTs in normal copper metabolism other than serving as a buffer for Cu+ is less
clear. A rather constant Cu2+/Zn2+ ratio is maintained in serum. During inflammation and ageing, the
ratio increases [71]. Extracellularly, Cu2+ can be scavenged and reduced by extracellular MT3 [72,73].
In MT3, bound Cu+ is redox-stable [74]. Different structures of MT are obtained depending on
whether copper is titrated into T or into Zn7MT, where metal-thiolate clusters have already established
a particular protein structure. The stoichiometry of seven divalent metal ions does not apply to
monovalent ions. Up to 12 Cu+ ions can be titrated into rabbit liver Zn-MT2. They bind in one Cu6S9
and one Cu6S11 (both Cu+-thiolate) cluster [75]. When Cu+ is titrated into T, two distinct Cu4-thiolate
clusters are formed with 12–14 cysteine residues involved in Cu+ ion binding [76]. The Cu8MT species
is a stable intermediate characterized by a breakpoint in the titration following the phosphorescence of
Cu+–S bonds, followed by the binding of an additional four Cu+ ions. A titration followed by ESI-MS,
identified Cu4S6 and Cu6S9 clusters in the β-domain followed by formation of Cu4S6 and Cu7Sx
clusters in the α-domain with clusters having specific emission and CD properties [77]. The binding of
additional copper ions up to a stoichiometric ratio of 20:1 was observed. The work was performed
with a human MT1A protein that contains 70 instead of the 61 amino acids of native MT1A. Clearly,
these supermetallated species have no significance under normal physiological conditions as the
availability of zinc and copper is controlled. Also, as discussed below, supermetallation has been
observed as a result of the nature of the mass spectrometric investigation. A 3D NMR structure of the
individual domains of murine MT1 demonstrates seven Cu+ ions bound in trigonal geometry, three in
the α-domain and four in the β-domain [78]. The copper protein structure is different from that of the
zinc protein. Thus, MT is a protein whose structure depends on the type of metal ion bound. A Cu4S8–9
cluster instead of the typical Zn3S9 cluster has also been observed in human MT3 [74]. There seems to
be a domain preference for Cu+ binding. The β-domain seems to have a marginally higher affinity for
Cu+ [77].
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7. Zn2+ Affinity for Human Metallothionein
The discovery of MT and its initial metal binding characterisation soon uncovered that this small,
highly cysteine-rich protein interacting with various metal ions and variable metal load in vivo is
a challenging system for biochemical and biophysical investigations. One of the pioneers in the
field, Bert L. Vallee, compared MT to a Sphinx, who only very slowly uncovers her deeply hidden
secrets. Indeed, after 60 years of MT research and over ten thousand research articles we are just
beginning to understand its biological function, which goes well beyond the originally postulated role
in storage of metal ions and includes regulatory functions in zinc and copper metabolism. One of
the most controversial MT parameters is its affinity for metal ions. It is critical for understanding
its function. While the affinity for metal ions was investigated from the beginning, a discussion of
the underlying assumptions is necessary to understand the conclusions. For many years, based on
a model of cooperative metal binding it was thought that seven Zn2+ ions are bound in MT with
identical and high affinity. Early spectroscopic studies on pH-dependent Zn2+ binding to MT indicated
a characteristic one-step binding mode that usually supports equivalence in metal ion binding to an
apo-protein [79]. Investigation of Zn2+ binding and characterization of the acidity of cysteines in T
(average pKaSH ≈ 8.9) allowed calculation of the apparent binding constant (Kb) of overall identically
bound Zn2+ ions in equine liver MT as 2× 1012 M−1 at pH 7.0 [79]. Similarly, investigations performed
in the 1980s showed that Zn7MT interacts with many chelators such as EDTA, NTA, H2KTSM or
terpyridyl causing Zn2+ ion dissociation from the protein [80,81]. Kinetic studies of Zn2+ transfer to
the chelators revealed two kinetic classes of Zn2+ ions in the protein. It has been suggested that there
are seven independent metal ion sites of two kinetic types. Using these concepts, stability constants
of Zn7MT were calculated using NTA and H2KTSM and competitors/chelators [81,82]. The same
apparent constants (1.8 × 1011 M−1) per Zn2+-binding site were determined at pH 7.4, independent
of whether the Zn2+ ions were grouped into two kinetic classes or treated as seven non-interacting
sites with equal affinity for Zn2+. The application of differential pulse polarography (DPP) in the
presence of metal chelators resulted in the determination of apparent stability constants of 1.3 × 1012
and 7.9 × 1011 M−1 in the case of rabbit MT2 and MT1, respectively [83]. Equilibration between MT
and the calcium chelator 5F-BAPTA, which also binds Zn2+ efficiently, has been used in 19F-NMR
spectroscopy to determine apparent Zn2+ binding constants of rabbit MT2 and human MT3 as 3.1
× 1011 and 6.2 × 1010 M−1, respectively [84]. In all these physicochemical approaches, one critical
assumption requires scrutiny in order to understand the limitation of the conclusions and what is
needed to obtain an accurate description of the system: Seven Zn2+ ions always were considered to be
thermodynamically equivalent and any possible difference in the stability of the seven Zn2+ ions was
not resolved. The pH-dependent Zn2+ binding and competition under this assumption are given in
Equations (1) and (2).
apo-MT + 7Zn2+ Zn7MT (1)
Zn7MT + chelator apo-MT + 7Zn-chelator (2)
Noteworthy, the existence of two species of the same protein, T and MT, was explained early
on by a high positive cooperativity of Zn2+ binding to the cysteine donors [68]. Cooperativity was
also inferred from spectroscopic observations [79]. 113Cd-NMR spectra were interpreted in terms of
positive cooperativity when the first couple of Cd2+ ions bind to the protein and NMR signals appear
simultaneously [32,79]. In case of Zn2+ ions, no method existed to examine cooperativity in binding.
Positive cooperativity implies that the binding of the first metal ion (first event) promotes the binding
of the remaining metal ions that would bind with higher affinity. If binding were to occur with high
positive cooperativity as proposed originally for ZnMT, the protein would buffer Zn2+ only in an
extremely narrow range. The current knowledge about binding constants seems to rule out such
positive cooperativity. Four Zn2+ ions seem to bind with similar, high affinity and what may appear as
cooperativity is a consequence of the metal determining protein structure for binding the additional
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metal ions in a clustered arrangement [30]. The association of the remaining three Zn2+ ions occurs
entirely in a sequential mode [30]. Such characteristics make MT a very good zinc buffer with a wider
range of pZn buffering as indeed necessary to cover the range of changes of cellular free Zn2+ ions.
The original assumption of all seven metal ions being thermodynamically equivalent in binding
introduces a major error by neglecting the possibility of more weakly bound metal ions. To demonstrate
how this bias occurred, one may consider two simple examples. In the first one, the affinities of all
seven metal ions are equal (logKb = 12.0) and the average binding constant of 12.0 applies to each of
them. In the second example, six metal ions are bound with the same high affinity of 12.0 but one ion
is bound with significantly lower affinity with a logKb value of 9.0. In this case, the assumption of
equivalence of all seven metal ions results in an average logKb value of 11.6, which is very similar to
the value of 12 in the first example, and not readily resolved by the methods employed in the past. The
average value does not reflect the more complex character of the protein in terms of metal binding and
does not indicate the presence of one metal ion bound with nanomolar affinity only.
Furthermore, in spectroscopic pH-titrations, it was assumed that all cysteine thiol residues have
the same pKa values, a scenario that is unlikely due to the differences in chemical environments of
the cysteines in the protein. The exact difference in acidity of the sulphur binding ligands cannot be
observed in UV-titrations due to the presence of 20 cysteines and overlapping dissociation events
(macroscopic vs microscopic pKa) [85,86].
Recent studies suggest that T, in particular the form one obtains when MT is demetallated, is not
in a random coil conformation and therefore there is the possibility that local structure influences the
acidity of particular cysteine residues [87,88]. We showed that cysteines of certain CXXC motifs in
zinc binding sites possess significantly different acid-base properties due to the presence of S· · ·H–N
hydrogen bonds [36,89]. Such hydrogen bonds exist in MTs [9,90,91] and could be responsible for
the observed structure of T despite the apparent lack of a defined overall structure of the protein.
The differences in acidity of cysteine thiols result in various affinities of the particular Zn2+ ions
at neutral pH. Therefore, assuming that the incremental increase of absorbance at ~220 nm due to
S− → Zn2+ charge transfer is linear and identical for each Zn–S bond in pH-dependent titrations
is not appropriate. In addition, the exact Zn2+ association and dissociation pathways in MT are
unknown and variable fractions of terminal and bridging sulphur donors per Zn2+ ion during the
binding processes make the direct spectroscopic titration method inconclusive and prone to error
when attempting to determine the affinities of seven chemically different Zn2+ ions. The application of
competing chelating reagents to determine the fraction of Zn2+ transferred during equilibration, such
as in the case of 5F-BAPTA and MT, is currently a standard procedure in metal affinity determination
of metalloproteins if the stability constant of the competing reagent is known under the condition
of the experiment [92,93]. However, different constants are obtained when various binding models
are considered. Assuming thermodynamic equivalence of seven Zn2+ ions results in an apparent
Zn2+ binding constant of ~1011 M−1 [81]. Remarkably, the use of NTA for the competition with
Zn7MT2 at various NTA/MT ratios showed high Zn2+-to protein affinity and equivalence of Zn2+ ions
when NTA was used at high reagent/protein molar ratios [30]. Decreasing the NTA concentration
resulted in higher Zn2+ transfer from MT than what is expected if all seven Zn2+ ions were bound
with the same affinity. This observation indicates differences in the affinity of the Zn2+ ions with
an additional indication that at least one Zn2+ ion binds with lower affinity to MT. The existence of
more weakly bound Zn2+ ions in MT has been shown in several publications using enzymatic assays.
The incubation of Zn7MT2 with the apo-forms of sorbitol dehydrogenase (SDH) and carboxypeptidase
A caused rapid recovery of enzymatic activity due to fast transfer of ~1 Zn2+ ion from MT [51,94,95].
Longer incubation of MT2 with apo-SDH at various ratios demonstrated that more than one Zn2+
ion can be transferred from MT [51], consistent with transfer of the more tightly bound Zn2+ ions.
However, SDH reconstitution with Zn2+ is significantly more efficient than expected based on a Zn2+
affinity of KbSDH = 1.6 × 1011 M−1 and the assumed presence of only tightly bound Zn2+ ions in MT
with an overall apparent binding constant of ~1012 M−1 [51]. All the above mentioned methods and
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enzymatic assays demonstrated that three classes of Zn2+ ions are present in MT: strongly bound Zn2+
with picomolar affinity, a weakly bound Zn2+ ion that exchanges fast, and some Zn2+ ions with high
picomolar affinity and transferred significantly slower to Zn2+ acceptors. The exact affinity values of
the weakly, i.e., with moderate affinity, bound Zn2+ ions were not determined by enzymatic assays
with recipient proteins. However, recovery of activity of the apo-form of alkaline phosphatase [95],
which binds two Zn2+ ions with binding constants of ~108 M−1 [96], and Zn2+ inhibition of protein
tyrosine phosphatase 1B with an apparent binding constant of 6.3 × 107 M−1 [51] clearly demonstrate
the presence of a weakly bound Zn2+ ion with nanomolar affinity in MT.
Besides spectroscopic and enzymatic methods and assays, electrospray mass spectrometry
provided new opportunities for determining metal ion affinity for MT. In the early literature on
the subject, it was reported that the relative abundances of various complexes in the samples can
be estimated from abundances of respective ions in the ESI-MS spectrum [97,98]. The application of
this method for Zn2+ metallation in several MT isoforms (MT1–3) shows that metal ion binding to
the protein is sequential rather than cooperative and several Zn1–7MT species are observed in mass
spectra at various Zn2+ to T ratios [99–102]. This observation is in contrast to the assumed equivalent
affinity of all seven Zn2+ ions as well as positive cooperativity in binding and supports the above
conclusion about the various affinities of zinc sites in MT. Zn2+ binding to human apo-MT1A (product
of the expression was a 72 amino acid protein instead of 61) was studied by ESI-MS in the presence of
apo-CA (carbonic anhydrase) as a Zn2+ competitor with a known high affinity for Zn2+ [102]. Using
the intensity of particular Zn1–7MT1A, apo-CA, and Zn-CA species from mass spectra and the known
Zn-CA stability (KbCA = 2.5 × 1011 M−1) [103], it was concluded that Zn2+ transfer to CA is sequential
and that the apparent binding constants of the seven Zn2+ ions (Kb1–Kb7) vary from 3.2 × 1012 to
6.3 × 1011 M−1. Although the method seems elegant, it is only qualitative. Our results of Zn2+ binding
to T performed in the presence of Zn2+ donors with various affinities (unpublished data) demonstrate
that metal binding analysis performed by ESI-MS does not assess completely the equilibria present in
solutions. Two recent papers published in mass spectrometry journals prove that investigations of
Zn2+-equilibria by electrospray ionization in the gas phase are not quantitative due to zinc deposition
or protein supermetallation during ESI-MS analysis [104,105].
Importantly, complicated systems with several metal ions bound to the protein should be
characterized using different methods in order to overcome the limitations of a single method.
The methods need to have the power to resolve small differences. When competitors are used
to determine Zn2+ affinity, their dynamic range for detecting changes should be taken into
account. In typical competition experiments, Zn2+ transfer is measured when the competitor is
saturated—ideally in the range of 20–80% or at least 10–90%. Depending on the (spectroscopic)
detection mode and the sensitivity one cannot determine quantitatively saturation changes below 10%
due to low signal to noise ratios. This automatically limits the range of affinities that can be determined
with a particular competitor to a binding constant of only one order or magnitude higher than the
Zn2+ binding constant of the competitor. If the protein binds more than one Zn2+ ion with potentially
different affinities, competitors with a larger dynamic range should be employed. Alternatively, a series
of competitors with various affinities toward Zn2+ can be employed.
We employed the extremely sensitive zinc fluorescent probe FluoZin-3 for the detection of Zn2+
transfer from human MT2 [30]. The linear dynamic range of FluoZin-3 is very large and the high
sensitivity of fluorimeters allows the detection of picomolar concentrations of Zn2+. The metal-free
probe is almost non-fluorescent and its saturation by Zn2+ increases fluorescence by about 25,000 times
when fully saturated [106]. Although FluoZin-3 binds Zn2+ with an apparent binding constant of
1.1 × 108 M−1 [23,107] its application allows measuring Zn2+ below 0.01% of Zn2+ saturation due to
its optical properties and the sensitivity of the fluorescence measurements. Thus, one can measure low
picomolar affinities (~1012 M−1) when using micromolar concentrations of the probe. The system is
fully reversible. Zn2+ binding to T in the presence of the probe and Zn2+ dissociation from Zn7MT2
and transfer to FluoZin-3 results in the same coordination mode and metal ion affinity. The most
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significant outcome of the investigation was the quantitative determination of three classes of Zn2+
affinities in MT. Four Zn2+ ions bind with high affinity of Kb1–4 ≈ 1012 M−1 with apparent high
cooperativity of Zn2+ binding in forming the Zn4MT species [30]. Another two Zn2+ ions bind to the
protein with lower 1010–1010.5 M−1 (Kb5, Kb6) affinity. And the seventh Zn2+ ion, regardless of whether
one measures association or dissociation, binds with nanomolar affinity (Kb7 ≈ 108 M−1). The same
values were determined when the slightly less sensitive fluorescent chelating agent RhodZin-3 was
used. The species Zn6MT could be involved in buffering zinc under conditions of zinc signalling
where low nanomolar concentrations of zinc are reached transiently. Under these conditions Zn7MT
could be formed.
This finding changed completely the understanding of how MT functions. Instead of being a
thermodynamic sink for Zn2+ as postulated previously (based on a high cooperativity model), it allows
MT to participate actively as a donor and acceptor of Zn2+ in the cell (Figure 2). The presence of a more
weakly bound Zn2+ ion in MT became the basis of some controversy but we believe our methodology is
sound and not fraud with the limitations of other methods used for the study of Zn2+-metallothionein
interactions [30]. A recent article on the thermodynamics of Zn2+ and Pb2+ interacting with MT3 is
remarkable in this regard [108]. Using isothermal titration calorimetry (ITC) and competition of EDTA
with Zn7MT3, exactly the same three classes of Zn2+ affinities were found. Although the study was
performed at pH 6.8 due to Pb2+ precipitating at higher pH, it was found that four Zn2+ ions are
bound with an overall apparent binding constant of 7 × 1010 M−1 and another two with 2 × 109 M−1.
The seventh Zn2+ ion was found to bind with a constant of 7 × 107 M−1. Adjusting those constants
to the pH of 7.4 used in our studies with FluoZin-3, not only the same stoichiometry but also almost
identical affinities of Zn2+ in MT3 compared to MT2 pertain. Moreover, Pb2+ ions bind to MT3 with the
same stoichiometry as Zn2+ with the classes for moderate and more weakly bound ions demonstrating
higher affinity relative to Zn2+.
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a long time in the absence of additional information regarding metallothionein’s function in metal
and redox metabolism, the signalling roles of Zn2+ ions, and the control of cellular zinc and copper.
The application of ultrasensitive fluorescent probes and sensors for the measurement of cellular free
Zn2+ concentration at the ~10−10 M level has changed the field as it established regulatory functions
of Zn2+ [37]. MT with seven Zn2+ ions bound with ~1012 M−1 affinity is incompatible with handling
free Zn2+ ions at concentrations varying from 10−8 to 10−11 M. Our investigations with the human
HT-29 colon cancer cell line demonstrated that cells under various physiological states have a surplus
of tight-binding zinc ligands of about 10% over total cellular Zn2+ [23]. We also showed that MT is the
most important component of the surplus of ligands for metals, indicating a crucial role in cellular zinc
buffering [23,109]. MT can buffer Zn2+ due to its varying affinities for Zn2+ (from ~108 to 1012 M−1),
which remarkably overlap with cellular transients in Zn2+ concentration. The simple presentation in
Figure 2 based on known affinities of human MT2 for Zn2+ demonstrates that MT does not exist as the
Zn7MT form under normal physiological condition but that Zn6MT and even Zn5MT species are the
most representative structures of cellular MT.
The existence of MT in not fully metal-loaded forms explains its buffering properties and its
functions as both a Zn2+ donor and a Zn2+ acceptor. Several investigations on Zn2+ transfer showed that
a mixture of Zn7MT and T, which in fact is the mixture of partially saturated species (Zn4–6MT) serves
as a donor for Zn2+ activating for example apo-metalloenzymes or inhibiting non-metalloenzymes
such as protein tyrosine phosphatase 1B, depending on prevailing Zn7MT to T ratios [51]. Clearly, this
discussion focused on mammalian MTs and human MTs in particular. The metal binding characteristics
and redox properties of MTs in non-mammalian species need to be determined and related to the
specific features of zinc and copper metabolism in these species. Such investigations are expected
to lead to a genuine understanding of the varying structures of the fascinating metal cluster in the
different MT families in relation to biological function.
Our investigations show that besides redox activity [20], the most important property for zinc and
copper metabolism is a function of MT as metal buffer under physiological conditions. MT in its fully
metal-loaded state in the 3D structures established by NMR spectroscopy and X-ray diffraction cannot
serve regulatory and signalling function of Zn2+ ions. The available 3D structures of MT represent
only a partial picture of the multiple MT structures present in the cellular environment. The other
partially saturated forms, for which structures with zinc are not known, constitute the complementary
forms required for satisfying the buffering properties of MTs. Several reports showed already that the
protein is present in tissues as a species that is not saturated with zinc and that the level of saturation
differs and depends on tissue localization and both physiological and pathological states. One needs
to recall that analytical methods for detection and quantitative analysis of partially metal-saturated
structures of individual MTs in vivo are not available. Thionein per se cannot be present in any tissue
when Zn2+ is present. Freely available zinc binding sites in Zn4–6MT species are responsible for the
protein frequently referred to as T.
One challenging issue for the future is the analysis of MT species in cells and tissues.
One possibility is to use antibodies towards particular species. However, the metamorphic nature of
the protein with structures depending on metal load and oxidation state and different structures of
Zn4–6MT and high coordination dynamics of Zn2+ ions in the protein may prevent the development
of such antibodies [110,111]. Another possibility are mass spectrometry techniques with combined
elemental and molecular resolution [26,112,113].
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